MedTrace Logo

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

NCT01647555 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2026-03-18

No results posted yet for this study

Summary

This study evaluates the skin toxicities in patients with epidermoid cancer, treated by Radiotherapy in association with Cetuximab.

Conditions

  • Epidermoid Head and Neck Cancer

Interventions

DRUG

Cetuximab

First cycle: 400 mg/m2 Next cycles: 250 mg/m2

RADIATION

Radiotherapy

Curative dose: 66 to 70 Gy

Sponsors & Collaborators

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Eric LARTIGAU, MD, PhD · Oscar Lambret Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-06
Primary Completion
2012-10-31
Completion
2014-10-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01647555 on ClinicalTrials.gov